Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NicVAX fMRI nicotine-challenge study in smokers
NL-OMON36778Phase 2Active, not recruiting
- Sponsor
- Maastricht University
- Start
- Mar 2011
- Modality
- Small Molecules, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of NicVAX and nicotine in nicotine dependence (2 arms), sponsored by Maastricht University. Primary endpoints: Correlation between nicotine-specific antibody levels and BOLD response and Correlation between nicotine-specific antibody levels and cognitive performance. Started Mar 2011; status: active, not recruiting.
02
Drugs
NicVAXnicotine
03
Conditions
nicotine dependence
Beyond the preview
Go deeper on NL-OMON36778.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36778.